Locations:
Search IconSearch
November 24, 2020/Cancer

Small-Incision Guarded Hydroaspiration in Patient with Small Iris Lesion

35-year-old presents with suspected iris melanoma

Arun Singh, MD

A 35-year-old presented at Cole Eye Institute with a lesion in the left iris. He had been seen annually by an outside optometrist for seven years. The lesion had not been noted previously.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The patient did not have any visual symptoms, and his visual acuity was 20/20 in both eyes.

The elevated pigmented lesion in the iris was associated with nodularity along the pupillary margin between the 10- and 11-o’clock position. There were no feeder vessels or neovascularization of the iris on exam.

OCT

Anterior segment OCT showed multinodular iris thickening.

Lesion

Although the lesion was small and appeared like a nevus, melanoma was suspected due to recent onset.

“Freckles and nevi of the iris are very common,” says Arun D. Singh, MD, Director of Ophthalmic Oncology at Cole Eye Institute. “All spots aren’t malignant, but there are some clues that can indicate which spots likely are.”

According to Dr. Singh, iris lesions suspicious for melanoma are those that:

  • Are newly detected or recently changed.
  • Distort the iris more than 3 mm in any dimension. “If it’s simply sitting on the iris, like a paint spot, we’re more apt to think it’s benign,” says Dr. Singh.
  • Contain blood vessels.
  • Have nodular elevations.

Excisional biopsy with pupilloplasty

Following discussion of treatment options, the patient agreed to undergo excisional biopsy of the lesion with pupilloplasty using a small-incision approach.

Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defect.

Almost 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, there are multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.

Advertisement

The next step, pupilloplasty, restores the iris to a near-normal shape with a suturing slip-knot technique since the iris does not have capacity to heal. This restoration of the iris not only repairs the cosmetic defect but helps prevent photophobia.

“Healing was much slower — six weeks or longer — with conventional techniques using the larger incision,” says Dr. Singh. “Distortion of the cornea was a problem too. If you’d make a 6 mm wound in the cornea, it would be irregular when it healed. Multiple smaller incisions allow faster healing. Patients typically have normal vision within a week or so.”

In this case, as clinically suspected, histopathology confirmed iris melanoma. All surgical margins were negative.

One day later, the patient’s vision was 20/30 with minimal postoperative inflammation.

Post-surgery

Four weeks following surgery, the patient’s vision was normal (20/20) without change in corneal astigmatism. The pupil size was equal between the two eyes in ambient light.

Patient eye

Now three years since surgery, the patient remains recurrence-free.

Three years postop

Better risk-benefit ratio than conventional iridectomy

Melanoma of the uvea is rare, occurring in just six per 1 million people. Approximately 10% of uveal melanoma occurs in the iris — extremely rare.

Two decades ago, the only option for removing uveal melanoma was an iridectomy with a large corneoscleral incision, requiring six weeks or more of healing and slow visual recovery. New techniques and better instrumentation now provide another option, with a better risk-benefit ratio, says Dr. Singh.

“Today, if I see a lesion growing, I recommend we remove it because I know we can do so safely with minimally invasive techniques,” he says. “In the past, we would just watch the lesion and hope to avoid a big surgery.”

Advertisement

Even small lesions can be suspicious for melanoma, which can be removed easily with low risk to the patient, he concludes.

Advertisement

Related Articles

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Ad